Congenital Hypertrophy of the Retinal Pigment Epithelium Presenting With Secondary Choroidal Neovascularization
Robert B. Garoon, J. William Harbour
Abstract
Robert B. Garoon, J. William Harbour
Abstract
The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:276-277.].
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:276-277.].
Key concepts: Choroidal neovascularization, Retinal pigment epithelium, Ophthalmology, Medicine, Bevacizumab, Retina, Neovascularization, Visual acuity